Compare AERT & ELUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AERT | ELUT |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.7M | 42.5M |
| IPO Year | 2021 | 2020 |
| Metric | AERT | ELUT |
|---|---|---|
| Price | $7.10 | $0.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 14.7K | ★ 42.9K |
| Earning Date | 02-09-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 110.87 | ★ 146.77 |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $70,014,000.00 | $12,293,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $10.83 |
| P/E Ratio | $26.81 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.26 | $0.50 |
| 52 Week High | $7.65 | $1.39 |
| Indicator | AERT | ELUT |
|---|---|---|
| Relative Strength Index (RSI) | 52.10 | 44.59 |
| Support Level | $6.11 | $0.80 |
| Resistance Level | $7.30 | $1.01 |
| Average True Range (ATR) | 0.28 | 0.07 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 64.19 | 25.01 |
Aeries Technology Inc is a professional and management services partner offering a range of management consultancy services for private equity sponsors and their portfolio companies with engagement models that are designed to provide a mix of deep vertical specialty, functional expertise, and digital systems and solutions to scale, optimize and transform a client's business operations. It supports and drives its client's growth across the globe by providing a range of management consultancy services involving professional advisory services and operations management services to build and manage dedicated delivery centers in appropriate locations based on customer business needs. It has more than 40 clients spanning across industry segments.
Elutia Inc develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients. Its products include CanGaroo, designed for implantable electronic devices, and SimpliDerm, used in soft tissue repair, with functions related to implant support and wound management. The company operates in two segments: Women's Health and Cardiovascular. The majority of revenue is derived from the Women's Health segment.